Xfinito Biodesigns Private Limited

Xfinito is building Xeuron.ai, an Intelligent platform to decipher the brain. The initial focus of Xeuron is the management of neurodegenerative disorders & biohacking.

The technology supporting neuromodulations and biohacking has been under development since 2012 and has undergone an informal validation with 300 patients. We have received govt grants of around $30K and pre-seed equity investment of about $100K

Customer Segments:
- Patients Wellness – Diabetes & Parkinsons
- Wellness Centers
- Rehab Center
- Pharmaceutical research and patient engagement programs
- Sports Medicine

Markets:
Asia, North America and Europe (Later can be expanded to Australia, Africa and South America)

Brain related disorders are common and mainly attributed to atrophy due to ageing. The main issue affecting these patients is declining personal and professional Quality of Life. Globally 10 Million people have Parkinson’s, 8% of the global population, i.e., 633 Million suffer from one or the other type of Neuropathy, and around 55 Million people globally have Dementia. The overall socio-economic burden due to neurodegenerative diseases is over 1.5 trillion dollars per year.

We are developing xeuron.ai, intending to decipher the brain and help millions affected by neurodegenerative, cognitive, learning and behavioural disorders; to prevent, monitor progression, support interventions, provide therapy; and improve their professional and personal quality of life. The platform uses data from biomarkers and digital markers through wearables to monitor the neuro-physical health of patients and provide AI backed actionable insights to improve their productivity and health

Currently, the competitors offer either passive footwear or smart insoles measuring pressure or temperature or both. Some of the smart insoles also offer motion analysis. However, none provide holistic measure nor evaluate nerve degenerations.

Passive Diabetic shoes do complement our offering and are potential collaborators. Similarly, some branded footwear giants like Skechers provide comfortable footwear and could collaborate for active footwear development.

The key differentiation & competitive advantage is intelligence backed by objective sensing to provide users with a personalized experience. The footwear and smartwatch could potentially detect various nerve degeneration much earlier than the manifestation of symptoms.

Finally, Given the healthcare space that we will be operating in, most footwear and wellness companies would either look to partner with us or acquire us instead of developing the system in-house, which gives us a defensible moat and opportunity to collaborate instead of competing.

The key differentiation & competitive advantage is intelligence backed by objective sensing to provide users with a personalized experience. The footwear and smartwatch could potentially detect various nerve degeneration much earlier than the manifestation of symptoms.

Primary Costs:
- Salaries
- Multisite Clinical Validation
- Manufacturing & Regulatory Approval
- Infrastructure for Quality product development

Revenue:
- B2C & B2B2C – Footwear & Smart Watch
- Technology Licensing
- B2B – Asset sales to the large brands
- Analytic services to the hospital for better treatment control

B2B2C
Sales Channel:
- Crowdfunding
- Online D2C & Affiliate Platform
- Patient Support Groups
Primary Costs:
- Salaries
- High-Performance Computing
- Genomics and blood biomarker testing centre
- Multisite Clinical Validation
- Manufacturing & Regulatory Approval
Revenue:
- D2C & B2B2C –for patients
- Technology Licensing
- B2B – Asset sales to the large brands
- Analytic services
Revenue Segments:
- Diabetic Patients
- Parkinson’s Patients
- Corporate Engagement Programs
- Wellness Centers
- Sports
- Orthopedics

- Human Resources
- Basic Infrastructure for Certifications
- Product Development & Marketing

We are expecting to dilute up to 10% of the startup in this round however, we are open to negotiation in case of strategic value from the investor.

With intensive customer interactions and in-depth technical feasibility study, we have mitigated most of the challenges and have developed a user-centric concept.

- Completed Acceleration program Launch and Zoom 3.0 from IIM Udaipur incubation Centre
-1 year at Atal Great Lakes Balachandra Incubator, Chennai
- Incubated and funded by Derbi Foundation

July 2020: Medtechnovation by IESA and Derbi Foundation
Sept 2020: Awarded Govt Grant through Nidhi Prayas Scheme DST
Feb 2021: Awarded Govt Grant through MSME Design Clinic Scheme by IISc
March 2021: Winner Flexible Electronics Challenge by IIT Kanput and Meity, India
Nov 2021: Finalist, Swadeshi Microprocessor challenge
Nov 2021: Winner AWS Campus Fund Grand Challenge 2021

Technology Patents to be filed shortly:
- Xeuron Technology
- Intelligent Computing & Processing
Utility Patents to be filed:
- The Novelty in Shoe and Placements
- Conductive Materials & Sensing Technology
The patents will help in additional revenue through non-exclusive technology licensing. We plan to innovate in materials shortly, giving us an edge for customized
footwear.
Trademark of xeuron.ai registered in India
Regulation - We initially intend to enter as Wellness Devices for the target patient pool and in 2 years acquire US FDA